• / Free eNewsletters & Magazine
  • / My Account
Home>Funds>Neuberger Berman High Yield Strategies

Neuberger Berman High Yield Strategies

  1. All
  2. Morningstar Articles
  3. 3rd Party
  1. FDA Grants Breakthrough Therapy Designation for Rituxan® (Rituximab) in Pemphigus Vulgaris

    FDA Grants Breakthrough Therapy Designation for Rituxan® (Rituximab) in Pemphigus Vulgaris

  2. Ambionics Achieves Breakthrough Development of Unique Child Prosthetic With Stratasys 3D Printing

    Ambionics Achieves Breakthrough Development of Unique Child Prosthetic With Stratasys 3D Printing

  3. Japan Equity CEFs Win the First Quarter

    These closed-end funds were unstoppable in early 2015; plus, did the first IPO of 2015 usher in a new era for CEF shareholders?

  4. Observations about Neuberger Berman Closed-End Fund Tender Offers

    Dan Plettner invests and receives income for securities research, including “buy-side” research. Dan licenses his own real time trading data to Covestor Ltd. (“Covestor”), frequently including positions discussed in his Morningstar Contributions. Covestor is a Registered Investment Advisor that ...

©2017 Morningstar Advisor. All right reserved.